Primary breast malignancies in adolescents and young adults: The MD Anderson Cancer Center experience.

S Samanta Catueno (1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX) A Adrian Gutierrez (The University of Texas MD Anderson Cancer Center, Houston, TX) A Amanda Balch (1The University of Texas MD Anderson Cancer Center, Houston, United States) L Lavinia P. Middleton (The University of Texas MD Anderson Cancer Center, Houston, TX) C Clark Andersen (2MD Anderson Cancer Center, Houston, United States) M Mariana Chavez Mac Gregor (The University of Texas MD Anderson Cancer Center, Houston, TX) J J. Andrew Livingston M Michael Roth (MD Anderson Cancer Center, Houston, Texas, United States) K Kelly Hunt (Medical University of South Carolina, Charleston, South Carolina, United States) N Najat C. Daw

Abstract

10006 Background: Primary malignancies of the breast rarely affect adolescents and are uncommon in young adults. Limited information is available about their clinicopathologic characteristics and outcomes. The 5-year overall survival (OS) for women with breast cancer, not including ductal carcinoma in situ, exceeds 90%. However, it remains unclear whether adolescents and young adults experience similar outcomes compared with older patients. Methods: We conducted a retrospective study of all patients aged 0–25 years with primary breast malignancies seen at MD Anderson Cancer Center between 2000 and 2024. Demographics, histology, staging, treatment, and outcome data were collected. Event-free survival (EFS) and OS were estimated using the Kaplan–Meier method. Log-rank test was used to analyze patient outcomes by histology. Results: A total of 110 patients were identified. Median age at diagnosis was 23.9 years (range, 15.7–25.5). Two patients were male, 44.9% were White, 27.7% Hispanic, and 15.9% Black. The most common tumor histology was invasive ductal carcinoma (n=83, 75.5%), followed by sarcoma and malignant phyllodes tumors (n=14, 12.7%), carcinoma in situ (n=7, 6.4%), and rare histologic subtypes (n=6, 5.5%). Family history of breast cancer was present in 53.6% of patients and ovarian cancer in 9%. Of 81 patients with germline genetic testing, 25 (30.9%) had a cancer predisposition syndrome: Li-Fraumeni (n=9), BRCA1 (n=8), BRCA2 (n=4), ATM (n=2), other (n=2). Eleven patients (10%) had metastatic disease at presentation to bone, lung, distant lymph nodes, and liver. Among the 96 carcinoma cases, 36 (37.5%) were estrogen or progesterone receptor-positive and HER2-negative; 25 (26%) were HER2+, and 32 (33%) were triple-negative. Of the 110 patients, 69 (62.7%) received neoadjuvant chemotherapy, 37.6% of whom achieved a pathologic complete response, and 46.3% a partial response. Most patients (92.7%) had surgery (mastectomy 87.2% or lumpectomy 9.8%), 67.2% received radiotherapy, and 25.4% targeted therapy. Following treatment, 56 (51%) patients received adjuvant endocrine therapy. The 5-year EFS and OS for the cohort were 30% (95% CI, 22.6-39.9) and 71.8% (95% CI 62.9-82), respectively, and are presented by histology in the table. EFS (p=0.023) but not OS (p=0.36) was associated with histologic type. Conclusions: Primary breast malignancies in adolescents and young adults have distinct characteristics with a high frequency of family history and genetic predisposition syndromes and appear to be associated with lower survival compared with breast cancer in older patients. Histology No. of patients 5-year EFS (%) (95% CI) 5-year OS (%) (95% CI) Invasive ductal carcinoma 83 31.3 (22.8, 43.1) 68 (57.9, 80) Sarcoma and malignant phyllodes tumors 14 28.6 (12.5, 65.4) 82.1 (62.1, 100) Carcinoma in situ 7 42.9 (18.2, 100) 100 (100, 100) Rare histologic subtypes 6 NA 100 (100, 100)

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
Pages 10006-10006
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (10)

S

Samanta Catueno

1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

A

Adrian Gutierrez

The University of Texas MD Anderson Cancer Center, Houston, TX

A

Amanda Balch

1The University of Texas MD Anderson Cancer Center, Houston, United States

L

Lavinia P. Middleton

The University of Texas MD Anderson Cancer Center, Houston, TX

C

Clark Andersen

2MD Anderson Cancer Center, Houston, United States

M

Mariana Chavez Mac Gregor

The University of Texas MD Anderson Cancer Center, Houston, TX

J

J. Andrew Livingston

M

Michael Roth

MD Anderson Cancer Center, Houston, Texas, United States

K

Kelly Hunt

Medical University of South Carolina, Charleston, South Carolina, United States

N

Najat C. Daw